| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
118,610,000 |
| Market
Cap: |
23.41(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.1974 - $0.2732 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Oncocyte is a molecular diagnostics company focused on developing and commercializing proprietary laboratory-developed tests to serve unmet medical needs across the cancer care continuum. Co.'s DetermaRx™ is a predictive molecular test for early-stage adenocarcinoma of the lung. This test provides information that a physician can use to help identify early-stage, surgically resected patients with Stage I and IIA non-squamous non-small cell lung cancer who are at high-risk of recurrence and may benefit from chemotherapy. Co.'s portfolio includes a gene expression-based test called DetermaIO™, which is being developed to identify patients most likely to respond to immunotherapy drugs.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
2,457,288 |
2,457,288 |
2,487,288 |
30,608,426 |
| Total Buy Value |
$7,167,688 |
$7,167,688 |
$7,174,135 |
$15,854,134 |
| Total People Bought |
3 |
3 |
4 |
10 |
| Total Buy Transactions |
4 |
4 |
5 |
20 |
| Total Shares Sold |
0 |
0 |
0 |
107,514 |
| Total Sell Value |
$0 |
$0 |
$0 |
$111,901 |
| Total People Sold |
0 |
0 |
0 |
2 |
| Total Sell Transactions |
0 |
0 |
0 |
2 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Andrews Ronald Asbury |
Former CEO |
• • – |
2022-12-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
250,000 |
583,212 |
|
- |
|
| Silverman Lou |
Director |
– • – |
2022-11-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,270 |
|
-27% |
|
| Last Andrew J. |
Director |
– • – |
2022-08-17 |
4 |
B |
$0.87 |
$17,400 |
D/D |
20,000 |
70,170 |
2.39 |
-63% |
|
| Arno Andrew |
Director |
– • – |
2022-08-17 |
4 |
B |
$0.90 |
$13,500 |
I/I |
15,000 |
15,000 |
2.1 |
-63% |
|
| Andrews Ronald Asbury |
President & CEO |
• • – |
2022-08-16 |
4 |
B |
$0.96 |
$38,400 |
D/D |
40,000 |
333,212 |
2.81 |
-67% |
|
| Griffith Melinda |
Director |
– • – |
2022-08-16 |
4 |
B |
$1.00 |
$10,000 |
D/D |
10,000 |
30,000 |
2.39 |
-67% |
|
| Arno Andrew |
Director |
– • – |
2022-08-16 |
4 |
B |
$0.97 |
$112,057 |
D/D |
115,523 |
282,049 |
2.39 |
-67% |
|
| Carter Jennifer L. |
Director |
– • – |
2022-08-16 |
4 |
B |
$0.95 |
$9,975 |
D/D |
10,500 |
30,500 |
2.39 |
-67% |
|
| Ross Douglas T. |
Chief Scientific Officer |
• – – |
2022-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
170,317 |
|
- |
|
| Last Andrew J. |
Director |
– • – |
2022-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
50,170 |
|
- |
|
| Griffith Melinda |
Director |
– • – |
2022-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
20,000 |
|
- |
|
| Arno Andrew |
Director |
– • – |
2022-08-15 |
4 |
B |
$0.93 |
$32,064 |
D/D |
34,477 |
166,526 |
2.39 |
-67% |
|
| Arno Andrew |
Director |
– • – |
2022-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
132,049 |
|
- |
|
| Gutfreund John Peter |
Director |
– • – |
2022-08-15 |
4 |
B |
$0.93 |
$23,250 |
I/I |
25,000 |
25,000 |
2.1 |
-67% |
|
| Gutfreund John Peter |
Director |
– • – |
2022-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
|
- |
|
| Carter Jennifer L. |
Director |
– • – |
2022-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
20,000 |
|
- |
|
| Kingsley Alfred D |
Director |
– • – |
2022-08-15 |
4 |
B |
$0.97 |
$9,700 |
D/D |
10,000 |
414,111 |
2.39 |
-67% |
|
| Kingsley Alfred D |
Director |
– • – |
2022-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
404,111 |
|
- |
|
| John Anish M. |
Chief Financial Officer |
• – – |
2022-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
150,000 |
|
- |
|
| Paulsen Gisela |
President & COO |
• – – |
2022-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
525,000 |
541,500 |
|
- |
|
| Gutfreund John Peter |
Director |
– • – |
2022-07-28 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,085,047 |
|
-45% |
|
| Arno Andrew |
Director |
– • – |
2022-06-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
122,049 |
|
- |
|
| Carter Jennifer L. |
Director |
– • – |
2022-06-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
|
- |
|
| Redmond Cavan M. |
Director |
– • – |
2022-06-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
120,863 |
|
- |
|
| Last Andrew J. |
Director |
– • – |
2022-06-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
40,170 |
|
- |
|
142 Records found
|
|
Page 2 of 6 |
|
|
